Belépés

NCT07572032Toboroz4. fázis

Delayed Initiation of ARNI and SGLT2i in Heart Failure With Corrected Aetiology (DELAY-HF), Pilot Study

Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. szept. 2.

Rövid összefoglaló (regiszter, angolul)

In patients with heart failure due to a reversible underlying cause-such as valvular heart disease or coronary artery disease-surgical or procedural correction of the underlying lesion (valve repair/replacement, TAVI, PCI, or CABG) frequently leads to spontaneous recovery of cardiac function, even without neurohormonal modulators. In this clinical setting, a substantial proportion of patients may not require the full set of guideline-directed medical therapies routinely prescribed for chronic HFrEF. The purpose of this study is to determine whether ARNI (angiotensin receptor-neprilysin inhibitor) and SGLT2 inhibitors are truly necessary in patients whose left ventricular function recovers spontaneously after treatment of a correctable cause of heart failure. The DELAY-HF trial (DELayed initiation of ARNI and SGLT2i in heart failure with corrected aetiologY) is a multicentre, randomised, open-label pilot trial with blinded end-point assessment (PROBE design) evaluating the safety and feasibility of a delayed-initiation strategy of ARNI and SGLT2i, compared with immediate initiation, in patients with heart failure whose underlying cause has been completely corrected by surgical or procedural intervention. A total of 80 patients (40 per arm) will be enrolled at four centres in South Korea. Adults with a preoperative left ventricular ejection fraction (LVEF) ≤40% who have undergone successful correction of a reversible cause of heart failure-either revascularization (PCI or CABG) for ischemic cardiomyopathy or valvular surgery (including TAVI) for left-sided valvular heart disease causing volume overload-will be randomized 1:1 to (1) delayed initiation, in which ARNI/SGLT2i are withheld for 6 months and started only in patients whose LVEF remains ≤40% at the 6-month assessment, versus (2) immediate guideline-directed medical therapy (GDMT) including ARNI/SGLT2i started shortly after the corrective procedure. All patients are followed for 12 months. The primary outcome is the absolute change in LVEF from baseline to 12 months. The between-group difference (delayed minus immediate) will be reported as a point estimate with a two-sided 95% confidence interval and evaluated against a pre-specified decision criterion (lower confidence limit above -5 percentage points). As a pilot trial, DELAY-HF is not powered for a confirmatory non-inferiority test; it aims to estimate the standard deviation of the primary outcome, recruitment and dropout rates, the rescue-therapy rate and safety data needed to design a subsequent confirmatory trial. Key secondary outcomes include cardiovascular and all-cause mortality, heart failure hospitalisation, additional echocardiographic indices, NT-proBNP, KCCQ-12 score, 6-minute walk distance, feasibility metrics, and a cost-effectiveness analysis. By comparing these two strategies, this pilot trial will provide preliminary estimates of the incremental contribution of ARNI and SGLT2i-to further LVEF recovery and to clinical outcomes-in patients who have already demonstrated spontaneous improvement in cardiac function after correction of the underlying cause, and will inform the design of a subsequent confirmatory trial addressing whether these agents are truly necessary in this population.

Állapot (regiszter)
Toboroz
Fázis (regiszter)
4. fázis
Vizsgálattípus
Beavatkozással járó
Résztvevők száma
80 (tervezett)
Első benyújtás
2026. ápr. 30.
Kezdés
2026. máj. 20.
Elsődleges befejezés
2028. máj. 20.
Fő szponzor
Kyungsub Song
NCT-szám
NCT07572032

Mit vállalsz

  • Vizsgálat típusa: Beavatkozással járó · 4. fázis
  • Tervezett résztvevők: 80
  • 2026. máj. 20. és az elsődleges befejezés (2028. máj. 20.) között
  • 4 helyszín, 1 országban
  • Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket

A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.

Ki nem vehet részt

Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.

Korábbi kezelés

  • Prior history of sustained ventricular tachycardia or ventricular fibrillation.
  • Greater-than-moderate paravalvular leak or residual mitral regurgitation after aortic or mitral valve surgery.

Más betegség

  • Incomplete revascularization in patients with coronary artery disease (residual significant disease in any major coronary territory: LAD, LCX, or RCA).
  • Uncontrolled hypertension on medical therapy (systolic blood pressure \> 160 mmHg).
  • Inability to tolerate ARNI, defined as inability to take sacubitril/valsartan 25 mg twice daily (e.g., due to symptomatic hypotension, history of angioedema, or bilateral renal artery stenosis).
  • Inability to tolerate SGLT2 inhibitors (e.g., type 1 diabetes mellitus or history of recurrent diabetic ketoacidosis).
  • Any other condition that, in the opinion of the investigator, would interfere with study participation or follow-up.

Laborértékek

  • Estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73 m².

Egyéb

  • Graft occlusion documented on coronary CT angiography after CABG. Planned pregnancy during the study period.

Kiket keres a vizsgálat

  • Age ≥ 18 years.
  • Preoperative left ventricular ejection fraction (LVEF) ≤ 40% on echocardiography.
  • Successful surgical or procedural correction of a correctable underlying cause of heart failure: Valvular heart disease: mitral valve surgery, aortic valve surgery, transcatheter aortic valve implantation (TAVI), or tricuspid valve surgery, OR Ischemic cardiomyopathy: complete revascularization by coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI).
  • Enrollment between 3 months before and 10 days after the corrective procedure.
  • Hemodynamically stable post-operative state with NYHA class I, defined at the time of randomization as: Systolic blood pressure ≥ 90 mmHg sustained for at least 6 hours; No up-titration of intravenous diuretics within the preceding 6 hours; No use of intravenous vasodilators within the preceding 6 hours; No use of intravenous inotropes within the preceding 24 hours; Heart rate 50-110 bpm and no clinical signs of volume overload.
  • Patients receiving ARNI or SGLT2 inhibitors prior to enrollment must complete a 1-week washout period before randomization.
    • Provision of written informed consent.

Életkor a regiszterben: 18 év – - · Nem: nők és férfiak · Egészséges önkénteseket nem fogad

A teljes feltétellista: ClinicalTrials.gov

Helyszínek (4)

Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.

HelyszínVárosOrszágHelyszín állapota
Keimyung University Dongsan Hospital
Ennek a helyszínnek vagy a koordinátora? Erősítsd meg az állapotát
DaeguDél-KoreaToboroz
Seoul National University Bundang Hospital
Ennek a helyszínnek vagy a koordinátora? Erősítsd meg az állapotát
Seongnam-siDél-KoreaToborzás még nem indult
Korea University Anam Hospital
Ennek a helyszínnek vagy a koordinátora? Erősítsd meg az állapotát
SeoulDél-KoreaToborzás még nem indult
Ajou University Hospital
Ennek a helyszínnek vagy a koordinátora? Erősítsd meg az állapotát
SuwonDél-KoreaToborzás még nem indult

Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.